Swiss Re’s Life Guide adds guidance on repurposed longevity drugs 11.08.2025, 14:38 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Swiss Re 165,44 USD -3,25 % Nasdaq OTC

Swiss Re Ltd / Key word(s): Product Launch/Research Update
Swiss Re’s Life Guide adds guidance on repurposed longevity drugs

11.08.2025 / 14:38 CET/CEST


Zurich, August 11, 2025 – A new class of longevity drugs is emerging, as medications originally developed for other conditions are being repurposed in the pursuit of a longer, healthier life. Medications such as metformin and rapamycin have gained popularity among health-conscious individuals, with some cases of people self-prescribing these medications. Given the uncertain long-term effects, Swiss Re has introduced guidance for underwriters on how to assess life insurance applicants who show signs of using these repurposed longevity drugs.

Swiss Re's August 2025 Life Guide update is part of Swiss Re's work to adapt underwriting guidance as new insights emerge on life and medical risks. Used by over 800 insurance companies across 100+ countries, Swiss Re’s Life Guide supports more than 23 million underwriting queries each year, enabling consistent, evidence-based decision-making in an evolving health landscape. Alongside updates on longevity medications, Life Guide now also includes an improved calculator for chronic kidney disease, prostate cancer risks and expanded medical risk assessment tools.

Natalie Kelly, Head of Global Underwriting, Claims and R&D at Swiss Re says: “Life Guide is the gold-standard toolkit for Life & Health underwriting. We've earned that status by staying ahead of developing risks. With repurposed medications, the clinical picture is still evolving. This update gives underwriters practical decision-making support—especially in cases where use of these drugs may be experimental or self-prescribed.”

Metformin and rapamycin are part of a growing list of substances being explored for anti-aging purposes. Metformin, originally used for managing type 2 diabetes, is being studied for its potential to slow aging by improving insulin sensitivity and reducing inflammation. Rapamycin, an immunosuppressant developed for organ transplant recipients, has been used in off-label attempts to extend lifespan.

Some of these drugs carry an uncertain risk. Rapamycin, for example, has raised concerns due to immunosuppressive effects and limited long-term data in animals. In response, Swiss Re has updated its Life Guide to provide underwriters with clear, evidence-based guidance on how to evaluate disclosures of these drugs, including when to apply a rating or defer the case to a medical officer.

For further information please contact Swiss Re Media Relations: + 41 (0)43 285 7171 or Media_Relations@Swissre.com.
Please use this link to access Swiss Re's press releases.

Swiss Re
The Swiss Re Group is one of the world’s leading providers of reinsurance, insurance and other forms of insurance-based risk transfer, working to make the world more resilient. It anticipates and manages risk – from natural catastrophes to climate change, from ageing populations to cyber crime. The aim of the Swiss Re Group is to enable society to thrive and progress, creating new opportunities and solutions for its clients. Headquartered in Zurich, Switzerland, where it was founded in 1863, the Swiss Re Group operates through a network of around 70 offices globally.

Cautionary note on forward-looking statements
Certain statements and illustrations contained herein are forward-looking. These statements (including as to plans, objectives, targets, and trends) and illustrations provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical fact or current fact. Further information on forward looking statements can be found in the Legal Notice section of Swiss Re's website.



End of Media Release


Language: English
Company: Swiss Re Ltd
Mythenquai 50/60
8022 Zurich
Switzerland
Phone: +41 (0) 43 285 71 71
E-mail: Media_Relations@swissre.com
Internet: www.swissre.com
ISIN: CH0126881561
Valor: 12688156
Listed: SIX Swiss Exchange
EQS News ID: 2182218

 
End of News EQS News Service

2182218  11.08.2025 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Werbung
Weiter abwärts?
Kurzfristig positionieren
Ask: 0,71
Hebel: 19
mit starkem Hebel
Ask: 2,36
Hebel: 6
mit moderatem Hebel
Smartbroker
Goldman Sachs
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: GU7VMB GG2R9N. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer